REXAHN REPORTS DATA FOR ONCOLOGY STUDIES
Rexahn Pharmaceuticals has reported the status of Phase I clinical trials of one of its leading oncology candidates, RX-0201. RX-0201 is a first-in-class signal inhibitor that directly blocks the production of Akt, a protein kinase, playing a key role in cancer progression.
The trial is designed to determine the safety and tolerability of RX-0201 in patients with cancer. The trial protocol calls for patients to undergo two cycles of two weeks on the drug and one week off. At 192 mg/M(2), patients showed no dose limiting toxicity. Currently, patients are being entered on 315 mg/M(2).